ID   PDE11_HUMAN             Reviewed;         933 AA.
AC   Q9HCR9; Q14CD1; Q53T16; Q96S76; Q9GZY7; Q9HB46; Q9NY45;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   15-MAR-2017, entry version 123.
DE   RecName: Full=Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A;
DE            EC=3.1.4.35;
DE            EC=3.1.4.53;
DE   AltName: Full=cAMP and cGMP phosphodiesterase 11A;
GN   Name=PDE11A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, SUBCELLULAR
RP   LOCATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RC   TISSUE=Prostate;
RX   PubMed=10906126; DOI=10.1074/jbc.M003041200;
RA   Yuasa K., Kotera J., Fujishige K., Michibata H., Sasaki T., Omori K.;
RT   "Isolation and characterization of two novel phosphodiesterase PDE11A
RT   variants showing unique structure and tissue-specific expression.";
RL   J. Biol. Chem. 275:31469-31479(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, ENZYME REGULATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Skeletal muscle;
RX   PubMed=10725373; DOI=10.1073/pnas.97.7.3702;
RA   Fawcett L., Baxendale R., Stacey P., McGrouther C., Harrow I.,
RA   Soderling S., Hetman J., Beavo J.A., Phillips S.C.;
RT   "Molecular cloning and characterization of a distinct human
RT   phosphodiesterase gene family: PDE11A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3702-3707(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), FUNCTION,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND ENZYME REGULATION.
RX   PubMed=11050148; DOI=10.1073/pnas.200355397;
RA   Hetman J.M., Robas N.M., Baxendale R., Fidock M., Phillips S.C.,
RA   Soderling S.H., Beavo J.A.;
RT   "Cloning and characterisation of two splice variants of human
RT   phosphodiesterase 11A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:12891-12895(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORMS 1; 2
RP   AND 4), AND TISSUE SPECIFICITY.
RX   PubMed=11121118; DOI=10.1046/j.1432-1327.2001.01866.x;
RA   Yuasa K., Kanoh Y., Okumura K., Omori K.;
RT   "Genomic organization of the human phosphodiesterase PDE11A gene:
RT   evolutionary relatedness with other PDEs containing GAF domains.";
RL   Eur. J. Biochem. 268:168-178(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=15800651; DOI=10.1038/sj.ijir.3901317;
RA   Loughney K., Taylor J., Florio V.A.;
RT   "3',5'-cyclic nucleotide phosphodiesterase 11A: localization in human
RT   tissues.";
RL   Int. J. Impot. Res. 17:320-325(2005).
RN   [8]
RP   ENZYME REGULATION, AND TISSUE SPECIFICITY.
RX   PubMed=16079899; DOI=10.1038/sj.ijir.3901377;
RA   Francis S.H.;
RT   "Phosphodiesterase 11 (PDE11): is it a player in human testicular
RT   function?";
RL   Int. J. Impot. Res. 17:467-468(2005).
RN   [9]
RP   DOMAIN, ENZYME REGULATION, AND MUTAGENESIS OF ASP-355.
RX   PubMed=16330539; DOI=10.1074/jbc.M511468200;
RA   Gross-Langenhoff M., Hofbauer K., Weber J., Schultz A., Schultz J.E.;
RT   "cAMP is a ligand for the tandem GAF domain of human phosphodiesterase
RT   10 and cGMP for the tandem GAF domain of phosphodiesterase 11.";
RL   J. Biol. Chem. 281:2841-2846(2006).
RN   [10]
RP   INVOLVEMENT IN PPNAD2, TISSUE SPECIFICITY, AND VARIANTS HIS-804 AND
RP   GLY-867.
RX   PubMed=16767104; DOI=10.1038/ng1809;
RA   Horvath A., Boikos S., Giatzakis C., Robinson-White A., Groussin L.,
RA   Griffin K.J., Stein E., Levine E., Delimpasi G., Hsiao H.P., Keil M.,
RA   Heyerdahl S., Matyakhina L., Libe R., Fratticci A., Kirschner L.S.,
RA   Cramer K., Gaillard R.C., Bertagna X., Carney J.A., Bertherat J.,
RA   Bossis I., Stratakis C.A.;
RT   "A genome-wide scan identifies mutations in the gene encoding
RT   phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical
RT   hyperplasia.";
RL   Nat. Genet. 38:794-800(2006).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-239, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
CC   -!- FUNCTION: Plays a role in signal transduction by regulating the
CC       intracellular concentration of cyclic nucleotides cAMP and cGMP.
CC       Catalyzes the hydrolysis of both cAMP and cGMP to 5'-AMP and 5'-
CC       GMP, respectively. {ECO:0000269|PubMed:10725373,
CC       ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148}.
CC   -!- CATALYTIC ACTIVITY: Guanosine 3',5'-cyclic phosphate + H(2)O =
CC       guanosine 5'-phosphate.
CC   -!- CATALYTIC ACTIVITY: Adenosine 3',5'-cyclic phosphate + H(2)O =
CC       adenosine 5'-phosphate.
CC   -!- COFACTOR:
CC       Name=a divalent metal cation; Xref=ChEBI:CHEBI:60240;
CC         Evidence={ECO:0000250};
CC       Note=Binds 2 divalent metal cations per subunit. Site 1 may
CC       preferentially bind zinc ions, while site 2 has a preference for
CC       magnesium and/or manganese ions. {ECO:0000250};
CC   -!- ENZYME REGULATION: Inhibited by 3-isobutyl-1-methylxanthine
CC       (IBMX), zaprinast and dipyridamole. cGMP acts as an allosteric
CC       activator. Weakly inhibited by Sildenafil (Viagra) and Tadalafil
CC       (Cialis); however, the fact that the protein is probably absent
CC       from testis, suggests that it is not biologically relevant and is
CC       not related with erectile dysfunction.
CC       {ECO:0000269|PubMed:10725373, ECO:0000269|PubMed:11050148,
CC       ECO:0000269|PubMed:16079899, ECO:0000269|PubMed:16330539}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=3.0 uM for cAMP (isoform 1) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         KM=1.4 uM for cGMP (isoform 1) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         KM=3.0 uM for cAMP (isoform 2) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         KM=1.5 uM for cGMP (isoform 2) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         KM=3.3 uM for cAMP (isoform 3) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         KM=3.7 uM for cGMP (isoform 3) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         KM=1.04 uM for cAMP (isoform 4) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         KM=0.52 uM for cGMP (isoform 4) {ECO:0000269|PubMed:10725373,
CC         ECO:0000269|PubMed:10906126, ECO:0000269|PubMed:11050148};
CC         Vmax=3.6 pmol/min/ug enzyme with cAMP as substrate (isoform 4)
CC         {ECO:0000269|PubMed:10725373, ECO:0000269|PubMed:10906126,
CC         ECO:0000269|PubMed:11050148};
CC         Vmax=3.9 pmol/min/ug enzyme with cGMP as substrate (isoform 4)
CC         {ECO:0000269|PubMed:10725373, ECO:0000269|PubMed:10906126,
CC         ECO:0000269|PubMed:11050148};
CC         Vmax=270 pmol/min/ug enzyme with cAMP as substrate (isoform 1)
CC         {ECO:0000269|PubMed:10725373, ECO:0000269|PubMed:10906126,
CC         ECO:0000269|PubMed:11050148};
CC         Vmax=120 pmol/min/ug enzyme with cGMP as substrate (isoform 1)
CC         {ECO:0000269|PubMed:10725373, ECO:0000269|PubMed:10906126,
CC         ECO:0000269|PubMed:11050148};
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:10906126}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=PDE11A4;
CC         IsoId=Q9HCR9-1; Sequence=Displayed;
CC       Name=2; Synonyms=PDE11A3;
CC         IsoId=Q9HCR9-2; Sequence=VSP_019900, VSP_019901;
CC       Name=3; Synonyms=PDE11A2;
CC         IsoId=Q9HCR9-3; Sequence=VSP_019899;
CC       Name=4; Synonyms=PDE11A1;
CC         IsoId=Q9HCR9-4; Sequence=VSP_019898;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is present in prostate, pituitary,
CC       heart and liver. It is however not present in testis nor in penis,
CC       suggesting that weak inhibition by Tadalafil (Cialis) is not
CC       relevant (at protein level). Isoform 2 may be expressed in testis.
CC       Isoform 4 is expressed in adrenal cortex.
CC       {ECO:0000269|PubMed:10725373, ECO:0000269|PubMed:11121118,
CC       ECO:0000269|PubMed:15800651, ECO:0000269|PubMed:16079899,
CC       ECO:0000269|PubMed:16767104}.
CC   -!- DOMAIN: The tandem GAF domains bind cGMP, and regulate enzyme
CC       activity. The binding of cGMP stimulates enzyme activity.
CC       {ECO:0000269|PubMed:16330539}.
CC   -!- DISEASE: Primary pigmented nodular adrenocortical disease 2
CC       (PPNAD2) [MIM:610475]: A rare bilateral adrenal defect causing
CC       ACTH-independent Cushing syndrome. Macroscopic appearance of the
CC       adrenals is characteristic with small pigmented micronodules
CC       observed in the cortex. Adrenal glands show overall normal size
CC       and weight, and multiple small yellow-to-dark brown nodules
CC       surrounded by a cortex with a uniform appearance. Microscopically,
CC       there are moderate diffuse cortical hyperplasia with mostly
CC       nonpigmented nodules, multiple capsular deficits and massive
CC       circumscribed and infiltrating extra-adrenal cortical excrescences
CC       with micronodules. Clinical manifestations of Cushing syndrome
CC       include facial and truncal obesity, abdominal striae, muscular
CC       weakness, osteoporosis, arterial hypertension, diabetes.
CC       {ECO:0000269|PubMed:16767104}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase
CC       family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PDE11AID44448ch2q31.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB036704; BAB16371.1; -; mRNA.
DR   EMBL; AB038041; BAB16372.1; -; mRNA.
DR   EMBL; AJ251509; CAB82573.1; -; mRNA.
DR   EMBL; AF281865; AAG32023.1; -; mRNA.
DR   EMBL; AJ278682; CAC15567.1; -; mRNA.
DR   EMBL; AB048423; BAB62712.1; -; Genomic_DNA.
DR   EMBL; AB048423; BAB62713.2; -; Genomic_DNA.
DR   EMBL; AB048423; BAB62714.1; -; Genomic_DNA.
DR   EMBL; AC073834; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC073892; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC083824; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC011998; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC012499; AAY14803.1; -; Genomic_DNA.
DR   EMBL; BC112393; AAI12394.1; -; mRNA.
DR   EMBL; BC114431; AAI14432.1; -; mRNA.
DR   CCDS; CCDS33334.1; -. [Q9HCR9-1]
DR   CCDS; CCDS42785.1; -. [Q9HCR9-2]
DR   CCDS; CCDS42786.1; -. [Q9HCR9-4]
DR   CCDS; CCDS46459.1; -. [Q9HCR9-3]
DR   RefSeq; NP_001070664.1; NM_001077196.1. [Q9HCR9-4]
DR   RefSeq; NP_001070665.1; NM_001077197.1. [Q9HCR9-2]
DR   RefSeq; NP_001070826.1; NM_001077358.1. [Q9HCR9-3]
DR   RefSeq; NP_058649.3; NM_016953.3. [Q9HCR9-1]
DR   UniGene; Hs.570273; -.
DR   ProteinModelPortal; Q9HCR9; -.
DR   SMR; Q9HCR9; -.
DR   STRING; 9606.ENSP00000286063; -.
DR   BindingDB; Q9HCR9; -.
DR   ChEMBL; CHEMBL2717; -.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB00820; Tadalafil.
DR   GuidetoPHARMACOLOGY; 1311; -.
DR   iPTMnet; Q9HCR9; -.
DR   PhosphoSitePlus; Q9HCR9; -.
DR   BioMuta; PDE11A; -.
DR   DMDM; 296439264; -.
DR   EPD; Q9HCR9; -.
DR   PaxDb; Q9HCR9; -.
DR   PeptideAtlas; Q9HCR9; -.
DR   PRIDE; Q9HCR9; -.
DR   Ensembl; ENST00000286063; ENSP00000286063; ENSG00000128655. [Q9HCR9-1]
DR   Ensembl; ENST00000358450; ENSP00000351232; ENSG00000128655. [Q9HCR9-2]
DR   Ensembl; ENST00000389683; ENSP00000374333; ENSG00000128655. [Q9HCR9-4]
DR   Ensembl; ENST00000409504; ENSP00000386539; ENSG00000128655. [Q9HCR9-3]
DR   GeneID; 50940; -.
DR   KEGG; hsa:50940; -.
DR   UCSC; uc002ulp.4; human. [Q9HCR9-1]
DR   CTD; 50940; -.
DR   DisGeNET; 50940; -.
DR   GeneCards; PDE11A; -.
DR   HGNC; HGNC:8773; PDE11A.
DR   HPA; HPA034560; -.
DR   MalaCards; PDE11A; -.
DR   MIM; 604961; gene.
DR   MIM; 610475; phenotype.
DR   neXtProt; NX_Q9HCR9; -.
DR   OpenTargets; ENSG00000128655; -.
DR   Orphanet; 189439; Primary pigmented nodular adrenocortical disease.
DR   PharmGKB; PA33121; -.
DR   eggNOG; KOG3689; Eukaryota.
DR   eggNOG; ENOG410XRI7; LUCA.
DR   GeneTree; ENSGT00760000119066; -.
DR   HOVERGEN; HBG101207; -.
DR   KO; K13298; -.
DR   OMA; ATNRSKW; -.
DR   OrthoDB; EOG091G04JU; -.
DR   PhylomeDB; Q9HCR9; -.
DR   TreeFam; TF316499; -.
DR   BRENDA; 3.1.4.17; 2681.
DR   Reactome; R-HSA-418457; cGMP effects.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   GeneWiki; PDE11A; -.
DR   GenomeRNAi; 50940; -.
DR   PRO; PR:Q9HCR9; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000128655; -.
DR   CleanEx; HS_PDE11A; -.
DR   ExpressionAtlas; Q9HCR9; baseline and differential.
DR   Genevisible; Q9HCR9; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0004115; F:3',5'-cyclic-AMP phosphodiesterase activity; TAS:Reactome.
DR   GO; GO:0047555; F:3',5'-cyclic-GMP phosphodiesterase activity; TAS:Reactome.
DR   GO; GO:0004114; F:3',5'-cyclic-nucleotide phosphodiesterase activity; TAS:ProtInc.
DR   GO; GO:0030552; F:cAMP binding; IEA:Ensembl.
DR   GO; GO:0030553; F:cGMP binding; IDA:UniProtKB.
DR   GO; GO:0004118; F:cGMP-stimulated cyclic-nucleotide phosphodiesterase activity; IDA:UniProtKB.
DR   GO; GO:0004112; F:cyclic-nucleotide phosphodiesterase activity; NAS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006198; P:cAMP catabolic process; IEA:Ensembl.
DR   GO; GO:0046069; P:cGMP catabolic process; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 1.10.1300.10; -; 1.
DR   Gene3D; 3.30.450.40; -; 2.
DR   InterPro; IPR003018; GAF.
DR   InterPro; IPR029016; GAF_dom-like.
DR   InterPro; IPR003607; HD/PDEase_dom.
DR   InterPro; IPR023088; PDEase.
DR   InterPro; IPR002073; PDEase_catalytic_dom.
DR   InterPro; IPR023174; PDEase_CS.
DR   Pfam; PF01590; GAF; 2.
DR   Pfam; PF00233; PDEase_I; 1.
DR   PRINTS; PR00387; PDIESTERASE1.
DR   SMART; SM00065; GAF; 2.
DR   SMART; SM00471; HDc; 1.
DR   SUPFAM; SSF55781; SSF55781; 2.
DR   PROSITE; PS00126; PDEASE_I; 1.
PE   1: Evidence at protein level;
KW   Allosteric enzyme; Alternative splicing; cAMP; cGMP;
KW   Complete proteome; Cushing syndrome; Cytoplasm; Hydrolase;
KW   Metal-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat.
FT   CHAIN         1    933       Dual 3',5'-cyclic-AMP and -GMP
FT                                phosphodiesterase 11A.
FT                                /FTId=PRO_0000247040.
FT   DOMAIN      217    370       GAF 1.
FT   DOMAIN      402    558       GAF 2.
FT   REGION      640    905       Catalytic. {ECO:0000250}.
FT   ACT_SITE    664    664       Proton donor. {ECO:0000250}.
FT   METAL       668    668       Divalent metal cation 1. {ECO:0000250}.
FT   METAL       704    704       Divalent metal cation 1. {ECO:0000250}.
FT   METAL       705    705       Divalent metal cation 1. {ECO:0000250}.
FT   METAL       705    705       Divalent metal cation 2. {ECO:0000250}.
FT   METAL       708    708       Divalent metal cation 2. {ECO:0000250}.
FT   METAL       734    734       Divalent metal cation 2. {ECO:0000250}.
FT   METAL       816    816       Divalent metal cation 1. {ECO:0000250}.
FT   BINDING     869    869       cAMP or cGMP. {ECO:0000250}.
FT   MOD_RES     162    162       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P0C1Q2}.
FT   MOD_RES     163    163       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P0C1Q2}.
FT   MOD_RES     239    239       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   VAR_SEQ       1    444       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:10725373}.
FT                                /FTId=VSP_019898.
FT   VAR_SEQ       1    358       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:11050148}.
FT                                /FTId=VSP_019899.
FT   VAR_SEQ       1    250       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10906126,
FT                                ECO:0000303|PubMed:11050148}.
FT                                /FTId=VSP_019900.
FT   VAR_SEQ     251    304       KTLVSKFFDVHAGTPLLPCSSTENSNEVQVPWGKGIIGYVG
FT                                EHGETVNIPDAYQ -> MLKQARRPLFRNVLSATQWKKVKI
FT                                TRLVQISGASLAEKQEKHQDFLIQRQTKTK (in
FT                                isoform 2). {ECO:0000303|PubMed:10906126,
FT                                ECO:0000303|PubMed:11050148}.
FT                                /FTId=VSP_019901.
FT   VARIANT     804    804       R -> H (in dbSNP:rs75127279).
FT                                {ECO:0000269|PubMed:16767104}.
FT                                /FTId=VAR_027056.
FT   VARIANT     867    867       R -> G (in dbSNP:rs61306957).
FT                                {ECO:0000269|PubMed:16767104}.
FT                                /FTId=VAR_027057.
FT   MUTAGEN     355    355       D->A: Induces a decrease in enzyme
FT                                activity due to the inability of cGMP to
FT                                bind and stimulate enzyme activity.
FT                                {ECO:0000269|PubMed:16330539}.
FT   CONFLICT    184    184       R -> Q (in Ref. 1; BAB16371, 4; BAB62712
FT                                and 6; AAI12394/AAI14432). {ECO:0000305}.
FT   CONFLICT    921    921       S -> SS (in Ref. 1; BAB16371/BAB16372, 2;
FT                                CAB82573, 3; AAG32023/CAC15567, 4;
FT                                BAB62712/BAB62713/BAB62714 and 6;
FT                                AAI12394/AAI14432). {ECO:0000305}.
SQ   SEQUENCE   933 AA;  104752 MW;  B725AE6963D6E799 CRC64;
     MAASRLDFGE VETFLDRHPE LFEDYLMRKG KQEMVEKWLQ RHSQGQGALG PRPSLAGTSS
     LAHSTCRGGS SVGGGTGPNG SAHSQPLPGG GDCGGVPLSP SWAGGSRGDG NLQRRASQKE
     LRKSFARSKA IHVNRTYDEQ VTSRAQEPLS SVRRRALLRK ASSLPPTTAH ILSALLESRV
     NLPRYPPTAI DYKCHLKKHN ERQFFLELVK DISNDLDLTS LSYKILIFVC LMVDADRCSL
     FLVEGAAAGK KTLVSKFFDV HAGTPLLPCS STENSNEVQV PWGKGIIGYV GEHGETVNIP
     DAYQDRRFND EIDKLTGYKT KSLLCMPIRS SDGEIIGVAQ AINKIPEGAP FTEDDEKVMQ
     MYLPFCGIAI SNAQLFAASR KEYERSRALL EVVNDLFEEQ TDLEKIVKKI MHRAQTLLKC
     ERCSVLLLED IESPVVKFTK SFELMSPKCS ADAENSFKES MEKSSYSDWL INNSIAELVA
     STGLPVNISD AYQDPRFDAE ADQISGFHIR SVLCVPIWNS NHQIIGVAQV LNRLDGKPFD
     DADQRLFEAF VIFCGLGINN TIMYDQVKKS WAKQSVALDV LSYHATCSKA EVDKFKAANI
     PLVSELAIDD IHFDDFSLDV DAMITAALRM FMELGMVQKF KIDYETLCRW LLTVRKNYRM
     VLYHNWRHAF NVCQLMFAML TTAGFQDILT EVEILAVIVG CLCHDLDHRG TNNAFQAKSG
     SALAQLYGTS ATLEHHHFNH AVMILQSEGH NIFANLSSKE YSDLMQLLKQ SILATDLTLY
     FERRTEFFEL VSKGEYDWNI KNHRDIFRSM LMTACDLGAV TKPWEISRQV AELVTSEFFE
     QGDRERLELK LTPSAIFDRN RKDELPRLQL EWIDSICMPL YQALVKVNVK LKPMLDSVAT
     NRSKWEELHQ KRLLASTASS SPASVMVAKE DRN
//
